Personalized chemotherapy sensitivity testing using patient-derived 3D tissue models and AI-driven architectural analysis
Purely Grow plans to offer a precision oncology platform that tests chemotherapy drugs directly on patient-derived tumor tissue reconstructed in a physiologically relevant 3D environment.
By combining ColFi3D™ tissue reconstruction with FibroAI™ architectural analysis, we provide data-driven insight into how a patient’s tumor may respond to specific treatments.
Our goal is to reduce trial-and-error and support more informed therapeutic decisions.
The Clinical Challenge
Cancer treatment often involves sequential testing of therapies:
- Patients may cycle through multiple chemotherapy regimens
- Response varies significantly between individuals
- Valuable time may be lost during ineffective treatment
- Toxic side effects can accumulate
Current laboratory models used in drug development do not accurately replicate the patient’s own tumor microenvironment.
This contributes to uncertainty in treatment selection.
Our Approach
Step 1: Tumor Sample Collection
A tumor biopsy obtained through standard clinical procedures is provided for analysis.
Step 2: 3D Tissue Reconstruction (ColFi3D™)
Tumor cells are embedded into a native collagen fiber scaffold that preserves structural and mechanical features of human tissue.
Cells self-organize into a matrix-rich 3D environment, allowing more physiologically relevant drug testing.
Step 3: Drug Sensitivity Screening
FDA-approved chemotherapy agents are applied to the reconstructed tissue.
Step 4: AI-Based Architectural Analysis (FibroAI™)
Rather than measuring only cell death, FibroAI™ evaluates:
- Structural organization
- Vascular-like network changes
- Tissue normalization patterns
- Architectural response to therapy
A quantitative sensitivity profile is generated.
What Makes This Different?
Traditional laboratory assays measure:
- Cell viability
- Proliferation
- Apoptosis markers
Our platform measures:
- Tissue-level organization
- Microenvironment response
- Structural normalization toward healthy architecture
This may detect meaningful therapeutic effects earlier and more comprehensively.
What Physicians Receive
A structured report that includes:
- Ranked drug response profile
- Tissue normalization scores
- Comparative architectural response metrics
- Supporting imaging analysis
This information is intended to support clinical decision-making in consultation with the treating oncologist.
Timeline
The full workflow is typically completed within approximately 14 days from receipt of the tumor sample.
Intended Use
This service is designed to provide supplementary laboratory data that may inform treatment discussions.
Treatment decisions remain under the direction of the patient’s licensed healthcare provider.
Who May Benefit
- Patients with newly diagnosed cancer evaluating first-line therapy
- Patients experiencing limited response to current treatment
- Oncologists seeking additional biological insight
- Clinical research collaborators
Commitment to Scientific Rigor
Our platform integrates:
- Human-derived matrix systems
- 3D tissue architecture modeling
- AI-based structural analysis
- Ongoing validation studies
We aim to strengthen the connection between laboratory modeling and patient outcomes.
Our Vision
We believe cancer treatment should be guided by how a patient’s own tissue responds — not solely by population averages.
By reconstructing human tissue architecture and analyzing it with artificial intelligence, we seek to reduce uncertainty and improve therapeutic confidence.
For clinical partnership inquiries or service availability, please contact Purely Grow.
